64Cu-DOTATATE Uptake in a Pulmonary Hamartoma
- 6 September 2022
- journal article
- editorial
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 48 (1) , 58-60
Abstract
DOTATATE PET/CT is frequently used to evaluate indeterminant pulmonary nodules suspected to be pulmonary carcinoid. We report an unexpected case of pulmonary hamartoma demonstrating 64Cu-DOTATATE uptake in a 43-year-old woman with a slowly enlarging pulmonary nodule. Histopathological staining showed somatostatin receptor 2 expression on vascular endothelial cells and a proportion of cartilage and smooth muscle cells within the hamartoma.Keywords
This publication has 7 references indexed in Scilit:
- 64Cu-DOTATATE PET/CT for Imaging Patients with Known or Suspected Somatostatin Receptor–Positive Neuroendocrine Tumors: Results of the First U.S. Prospective, Reader-Masked Clinical TrialJournal of Nuclear Medicine, 2020
- 68Ga-DOTATATE PET/CT in Nonneuroendocrine TumorsClinical Nuclear Medicine, 2017
- Head-to-Head Comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT: A Prospective Study of 59 Patients with Neuroendocrine TumorsJournal of Nuclear Medicine, 2016
- Somatostatin Receptor Imaging with68Ga DOTATATE PET/CT: Clinical Utility, Normal Patterns, Pearls, and Pitfalls in InterpretationRadioGraphics, 2015
- A Comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in Pulmonary Neuroendocrine TumorsJournal of Nuclear Medicine, 2009
- Functional imaging in differentiating bronchial masses: an initial experience with a combination of 18F-FDG PET-CT scan and 68Ga DOTA-TOC PET-CT scanAnnals of Nuclear Medicine, 2009
- Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endotheliumBritish Journal of Cancer, 2005